Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Mol Cancer Res. 2014 Nov 12;13(3):575–583. doi: 10.1158/1541-7786.MCR-14-0411

Figure 3. Effect of dasatinib treatment on Fn14 protein levels in EGFR-mutant HCC2279 and H1975 cells and EGF-stimulated, EGFR wild-type A549 cells.

Figure 3

(A) HCC2279 and H1975 cells were serum-starved overnight and then either treated with vehicle or dasatinib (30 nM) for 8 hours. Cells were harvested and Fn14, p-Src, Src, and GAPDH levels were analyzed by Western blotting. (B) A549 cells were serum-starved overnight and then either left untreated or treated with EGF (50 ng/mL) alone, EGF and drug vehicle, or EGF and dasatinib (30 nM) for the indicated time periods. Cells were harvested and Fn14, p-Src, Src, p-EGFR, EGFR, and GAPDH levels were analyzed by Western blotting.